Mats Lindskog
Director/Miembro de la Junta en WNTRESEARCH AB .
Perfil
Mats Lindskog is currently working as a Director at Wntresearch AB and as a Chief Business Officer at Oblique Therapeutics AB.
He holds a doctorate degree from the Royal Institute of Technology.
Cargos activos de Mats Lindskog
Empresas | Cargo | Inicio |
---|---|---|
WNTRESEARCH AB | Director/Miembro de la Junta | 01/01/2023 |
Oblique Therapeutics AB
Oblique Therapeutics AB Pharmaceuticals: MajorHealth Technology Oblique Therapeutics AB is a privately held Swedish biotech company that develops innovative new medicines for severe diseases with a large unmet medical need, focusing on pain and advanced cancer. The company is based in Gothenburg, Sweden. The company uses abiprot®, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome. The portfolio comprises several antibody candidates and the small molecule ot-1096 in triple-negative breast cancer. In addition, two antibody programs are run in R&D collaborations with pharma companies. The company was founded in 2015 by Jan Owe Owesson Orwar, and Christer Nordstedt has been the CEO of the company since 2022. | Corporate Officer/Principal | - |
Formación de Mats Lindskog.
Royal Institute of Technology | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
WNTRESEARCH AB | Health Technology |
Empresas privadas | 1 |
---|---|
Oblique Therapeutics AB
Oblique Therapeutics AB Pharmaceuticals: MajorHealth Technology Oblique Therapeutics AB is a privately held Swedish biotech company that develops innovative new medicines for severe diseases with a large unmet medical need, focusing on pain and advanced cancer. The company is based in Gothenburg, Sweden. The company uses abiprot®, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome. The portfolio comprises several antibody candidates and the small molecule ot-1096 in triple-negative breast cancer. In addition, two antibody programs are run in R&D collaborations with pharma companies. The company was founded in 2015 by Jan Owe Owesson Orwar, and Christer Nordstedt has been the CEO of the company since 2022. | Health Technology |
- Bolsa de valores
- Insiders
- Mats Lindskog